By Colin Kellaher


Shares of Zoetis fell in premarket trading Friday after The Wall Street Journal reported that the company's arthritis drugs for dogs and cats have come under scrutiny over possible side effects.

Zoetis shares, which closed Thursday at $162.73, were recently down 4.4% to $155.60 in premarket trading.

According to The Journal, health regulators in the U.S. and Europe have received thousands of reports of side effects and are conducting reviews of the drugs, sold as Librela for dogs and Solensia for cats.

Zoetis says the medicines are safe, with reports of side effects representing well less than 1% of the more than 18 million combined shots administered to date, according to the report.


Write to Colin Kellaher at colin.kellaher@wsj.com


(END) Dow Jones Newswires

04-12-24 0747ET